Depression may stem from an energy production problem in brain cells, study finds

Researchers have found that brain and blood cells in young adults diagnosed with major depressive disorder behave differently from healthy cells in a specific and measurable way: they produce more energy molecules at rest, but cannot increase that output when demand rises. In healthy individuals, cells ramp up energy production in response to increased workload. In people with depression, that on-demand scaling appears to be impaired. The finding suggests that depression is at least partly a disorder of cellular energy metabolism, not just a chemical imbalance in neurotransmitters.

That distinction matters clinically. The dominant treatment paradigm for depression for the past several decades has centered on serotonin, dopamine, and norepinephrine. SSRIs, SNRIs, and related drug classes work by adjusting how these chemicals behave in synapses. They help many people. But they fail to produce adequate relief in a substantial portion of patients. A 2006 NIMH-funded study called STAR*D found that after four consecutive treatment attempts with different antidepressants, roughly 30 percent of patients still had not achieved remission. A metabolic explanation for some of those cases would point toward entirely different treatment targets.

What the cells are actually doing differently

The study measured mitochondrial function in both neurons derived from induced pluripotent stem cells and in peripheral blood mononuclear cells taken from participants. Mitochondria are the cellular structures responsible for producing adenosine triphosphate, the molecule cells use as their primary energy currency. The research team used a technique called Seahorse extracellular flux analysis to measure oxygen consumption rates in cells from participants with depression and from matched healthy controls.

In cells from participants with major depressive disorder, baseline oxygen consumption rates were elevated, meaning the cells were working harder at rest to maintain basic function. When researchers applied a stimulus that should trigger increased mitochondrial output, the depressed-group cells showed a blunted response. They had less respiratory reserve capacity than controls, which is the technical term for a cell's ability to increase energy production above its resting level when demand spikes. Healthy cells maintain a buffer of extra capacity for exactly that purpose. Cells from the depressed group had a significantly smaller buffer.

Why this explains cognitive fatigue in depression

Cognitive tasks like concentrating, making decisions, or holding multiple pieces of information in working memory are metabolically expensive for the brain. The prefrontal cortex, which handles most of those functions, consumes disproportionately large amounts of ATP relative to its size during active cognitive work. If the cells supplying that energy cannot scale up production on demand, the brain would be expected to struggle with precisely the kinds of tasks that people with depression commonly report difficulty with: sustained attention, mental clarity, and effortful thinking.

The World Health Organization's International Classification of Diseases includes cognitive fatigue and difficulty concentrating as diagnostic criteria for major depressive disorder. These symptoms have traditionally been explained through neurotransmitter frameworks, but those frameworks have difficulty accounting for why cognitive impairment often persists even after mood symptoms improve with antidepressant treatment. A mitochondrial reserve deficit would explain persistence of cognitive symptoms independently of serotonin levels, because the energy problem is structural rather than chemical.

The mitochondrial hypothesis of depression and prior research

The idea that mitochondrial dysfunction plays a role in psychiatric disorders is not new, but it has remained a minority hypothesis relative to neurotransmitter-focused research. A 2019 meta-analysis published in JAMA Psychiatry reviewed 17 studies examining markers of mitochondrial function and oxidative stress in people with major depressive disorder and found consistent evidence of elevated oxidative stress and altered mitochondrial activity across studies, though the direction and specifics varied. What distinguishes the new research is the directional specificity of the finding: not just that mitochondria behave differently in depression, but precisely how they differ, with elevated baseline activity alongside impaired on-demand scaling.

Prior research has also noted that several interventions with documented antidepressant effects have known impacts on mitochondrial function. Exercise increases mitochondrial biogenesis, the process of creating new mitochondria in cells, through pathways involving PGC-1alpha, a protein that regulates mitochondrial density in muscle and brain tissue. A 2016 meta-analysis of 25 randomized controlled trials published in JAMA Psychiatry found that exercise produced significant reductions in depression symptoms compared to control conditions, with a standardized mean difference of 0.67, which is a moderate to large effect size by clinical standards.

What treatment implications this research opens up

If reduced mitochondrial reserve capacity is a consistent feature of major depressive disorder, then interventions that improve mitochondrial function could become a target for drug development or as adjuncts to existing treatments. Several compounds already in use for other conditions have mitochondrial effects: metformin, commonly prescribed for type 2 diabetes, has been associated with improved mitochondrial efficiency in multiple tissue types. N-acetylcysteine, a supplement used clinically for acetaminophen overdose, has shown modest antidepressant effects in randomized trials and reduces oxidative stress that damages mitochondrial membranes.

The research team, based at the University of Cambridge, published their findings in the journal Nature Mental Health and indicated their next phase of work will test whether the mitochondrial reserve deficit they observed correlates with specific depression subtypes or treatment response profiles. If patients with this metabolic signature respond differently to SSRIs than patients without it, that would provide a potential biomarker for stratifying patients toward different treatment approaches. A follow-up study involving a larger cohort with neuroimaging data to correlate mitochondrial function with prefrontal cortex activity is planned to begin recruitment in late 2026.